This is an open-label, non-controlled, non-randomized study to assess the therapeutic efficacy of 177Lu-AB-3PRGD2 in patients with various solid tumors who will undergo radioligand therapy using 177Lu-AB-3PRGD.
Ability to understand and willingness to sign a written informed consent document.
Age 18 and older.
Confirmed unresectable or metastatic refractory cancer with measurable disease per RECIST (version 1.1) (i.e. at least 1 lesion > 1 cm or lymph node > 1.5 cm in short axis).
Progressive disease after multiple-lines treatment.
Participant on any chemical anticoagulant including antiplatelet agents (excluding ASA).
Participants with Class 3 or 4 NYHA Congestive Heart Failure.
Clinically significant bleeding within two weeks before trial entry (e.g. gastrointestinal bleeding, intracranial bleeding).
Pregnant or lactating women.